727 |
Updated Antiplatelet Therapy After PCI; Prasugrel, AZD6140..;The Future We Can Expect in Routine Practice? |
David Joel Cohen |
May. 13. 09 |
726 |
What Is the Optimal Duration of Dual Antiplatelet Therapy Following DES Treatment? |
David E. Kandzari |
May. 13. 09 |
725 |
Updated Data and Clinical Application of Triple Antiplatelet Therapy: The Answer to Patients with CYP 2C19 Polymorphism and High Post-Treatment Platelet Reactivity After Clopidogrel? |
Seung-Whan Lee |
May. 13. 09 |
724 |
Polymorphism in Metabolism of Clopidogrel and Its Clinical Implication and Management |
Alexandra J. Lansky |
May. 13. 09 |
723 |
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology? |
Matthew Price |
May. 13. 09 |
722 |
The Limitation of Current CTO Recanalization Strategy and Future Direction |
Osamu Katoh |
Jan. 19. 09 |
721 |
HDL therapy via plasmapheresis |
|
Jan. 07. 09 |
720 |
SEARCH trial |
|
Jan. 07. 09 |
719 |
Approach trial |
|
Jan. 07. 09 |
718 |
The Impact of Hypertriglyceridemia on Clinical Outcome of Patients Subjected to Percutaneous Coronary Intervention in the Presence of High and Low High-density Lipoprotein Cholesterol |
|
Jan. 07. 09 |